Cholesterol ManagementJun 4, 2026
A lower dose of a statin paired with ezetimibe can deliver the same cardiovascular protection as cranking the statin dose to maximum, while causing fewer muscle complaints, less diabetes risk, and better long-term adherence. That's the core finding from large randomized trials and meta-analyses comparing these two strategies head to head.
If you've been told you need a statin but worry about tolerability, or if you're already on a high dose and struggling with side effects, this combination approach is worth understanding. The evidence is strong enough that it's reshaping how clinicians think about lipid-lowering therapy, especially for older adults and people prone to statin-related problems.
GLP-1Jun 4, 2026
In a trial of 27,564 patients followed for over two years, evolocumab (Repatha) cut LDL cholesterol by 59% and lowered major cardiovascular events by 15%, with no meaningful difference in adverse events versus placebo aside from a small uptick in injection-site reactions. Weight loss was not on the list of effects, then or in any subsequent analysis.
If you have heard that an injectable drug helps with weight, you are probably thinking of a different class. Wegovy, Zepbound, Ozempic, and Mounjaro are GLP-1 receptor agonists, designed specifically to drive weight loss. Repatha was designed for cholesterol.
They are all injections, administered weekly or monthly, and all expensive. They do not do the same thing.
Cholesterol ManagementJun 4, 2026
After 9 hours at hot room temperature, Repatha (evolocumab) loses about 10% of its PCSK9-inhibiting activity, and after 18 hours that loss climbs to 15%.
That matters because the drug's job is to drop LDL cholesterol by roughly 60%, which translates into about a 15% reduction in the combined risk of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, and coronary revascularization in people with established cardiovascular disease. A medication doing that much heavy lifting shouldn't be quietly losing potency on a kitchen counter.
So how long can a Repatha pen actually sit out of the fridge before you should worry? The honest answer depends on three variables: ambient temperature, time, and whether you put a cold pack near it.
Cholesterol ManagementJun 4, 2026
In a trial of 27,564 people with established heart disease, Repatha pushed average LDL cholesterol from 92 mg/dL down to 30 mg/dL. That is roughly a 60% drop, achieved on top of statins, sustained for years. The same trial also showed an 18% drop in major cardiovascular events: heart attacks, strokes, and the procedures used to fix them.
Most articles you find about Repatha (evolocumab) are either drug-company brochures or anonymous internet comment threads. The actual reviews you should care about live inside randomized trials and real-world registries that have now followed hundreds of thousands of patient-years on this medication. The picture they paint is consistent: a powerful LDL-lowering injection with a side-effect profile that surprises people for how light it is, paired with hard outcome data that explain why cardiologists keep adding it to high-risk patients despite the price tag.
Cardiovascular HealthJun 4, 2026
Praluent (alirocumab) can cut LDL cholesterol by roughly 60% in patients already taking the highest tolerated statin dose. That alone is striking. But the more compelling finding is what happens next: in a trial of nearly 19,000 people who had recently suffered a heart attack or acute coronary event, that LDL drop translated into a 15% reduction in major cardiovascular events, including heart attack, stroke, and cardiovascular death. The catch is that not everyone gets the same payoff. Where your LDL starts and whether you have diabetes dramatically change the math.
Praluent is a subcutaneous injection, not a pill. It belongs to a class called PCSK9 inhibitors, and it's approved specifically as an add-on for adults with familial hypercholesterolemia or established cardiovascular disease who need more LDL lowering than statins alone can deliver. This isn't a first-line treatment. It's the next step when statins aren't getting the job done.
Cholesterol ManagementJun 4, 2026
In a real-world registry of patients on PCSK9 inhibitors, 71.1% of all reported side effects resolved during follow-up. That's not a marketing claim. It's the headline finding from a Dutch pharmacovigilance dataset that tracked what actually happened to people who flagged a problem with the drug.
If you just started Repatha (or are about to), this is the question that matters: will the sting at the injection site, the muscle ache, the flu-like feeling stick around, or pass? The answer depends on which side effect, but the data is reassuring across most of them. Long-term trials following patients for up to 8.4 years on Repatha show that adverse event rates don't climb over time, and in some cases actually decline.
Cholesterol ManagementJun 4, 2026
After up to 8.4 years on Repatha, with LDL cholesterol pushed below 20 mg/dL in many patients, the rate of serious adverse events, new-onset diabetes, hemorrhagic stroke, and neurocognitive complaints did not exceed what was seen on placebo, and did not climb over time.
That's the headline finding from FOURIER-OLE, the open-label extension of the original Repatha trial. It's the longest controlled safety dataset we have for any PCSK9 inhibitor, and it directly addresses the two questions most people taking Repatha eventually ask: does this drug get worse the longer you stay on it, and does pushing LDL this low cause harm we haven't seen yet.
The short answers are no and no. The longer answer is more interesting, because there are real wrinkles, real critiques, and real subgroup nuances worth knowing if you're going to be on this medication for a decade or more.
MedicationsJun 4, 2026
Leqvio (inclisiran) is a twice-yearly injection that lowers LDL cholesterol by silencing PCSK9 production in the liver. Across multiple phase 3 trials enrolling over 3,600 patients, its overall safety profile was comparable to placebo, with injection-site reactions as the main differentiator. Here is what the clinical trial data actually shows about side effects, long-term tolerability, and safety in specific patient groups.
MedicationsJun 4, 2026
Praluent (alirocumab) and Repatha (evolocumab) are injectable PCSK9 inhibitors prescribed when statins alone can't bring LDL cholesterol low enough. Both cut LDL by 50-65% and reduce heart attacks and strokes. The real differences are subtle but worth understanding.
MedicationsJun 4, 2026
Rosuvastatin is the most potent statin per milligram, lowering LDL cholesterol by 43% to 55% across its dose range. Your starting dose depends on cardiovascular risk, how far LDL needs to drop, and whether you have existing heart disease.
MedicationsJun 4, 2026
Repatha (evolocumab) is a PCSK9 inhibitor that lowers LDL cholesterol by about 55-60% on top of statins. It is prescribed when statins alone are not enough or when patients cannot tolerate them. Repatha works differently from statins, targeting a specific protein in the liver rather than blocking cholesterol production. Its side effect profile reflects that difference. Here is what clinical trial data and post-marketing surveillance actually show.
MedicationsJun 4, 2026
Rosuvastatin 5 mg is one of the most studied low-dose statins available. Clinical trial data from over 16,000 patients shows it is well tolerated, with serious side effects occurring at rates similar to placebo.
Cholesterol ManagementJun 3, 2026
The monthly 420 mg Repatha dose delivered by Pushtronex packed three times the medication of the every-two-week shot into a single application, and it lowered LDL cholesterol by roughly 55 to 75%, the same range as the every-two-week schedule. That equivalence was the whole reason the monthly dosing option existed in the first place.
If you remember Pushtronex, you may have used it. If you have not, here is what it was: a hands-free, on-body delivery system that infused the 420 mg monthly dose of Repatha (evolocumab) over a few minutes once you applied it to your stomach or thigh. Amgen has since shifted Repatha distribution toward the SureClick auto-injector and pre-filled syringe formats, but the underlying monthly dosing option that Pushtronex delivered remains.
The question that matters to anyone searching for this is the same now as it was then: did the monthly schedule actually work, and what should you do if you were on it?
Cholesterol ManagementJun 3, 2026
Rosuvastatin at just 10 mg lowers LDL cholesterol by roughly 45% on average. That's a significant drop from what's technically classified as a "moderate-intensity" dose, and it puts this single pill in striking distance of higher-dose regimens that come with more side effect concerns. But the story doesn't end at cholesterol numbers. The same research that confirms rosuvastatin's potency also flags real risks around kidney health, diabetes, and genetic vulnerabilities that most people never hear about.
What makes 10 mg a particularly interesting dose is its versatility. It sits at a sweet spot: strong enough to be a workhorse for high-risk patients, low enough to combine with other drugs for even deeper LDL cuts, and capped as the maximum recommended dose for people with advanced kidney disease. Understanding where it shines and where it stumbles matters if you're taking it or considering it.
Digestive DisordersJun 3, 2026
Psyllium, the single ingredient in Metamucil, has clinical trial evidence behind four distinct health outcomes: relieving constipation, lowering LDL cholesterol, improving blood sugar control in type 2 diabetes, and supporting modest weight loss. That makes it one of the best-studied fiber supplements you can buy.
The catch is that these results consistently require around 10 grams per day or more, taken for at least several weeks. A single spoonful on a random Tuesday morning probably isn't doing much.
MedicationsJun 3, 2026
Repatha (evolocumab) is a PCSK9 inhibitor given as a subcutaneous injection to lower LDL cholesterol. It is prescribed for adults whose cholesterol remains above goal despite statin therapy, including those with established cardiovascular disease or familial hypercholesterolemia. The injection can be self-administered at home using a prefilled autoinjector or syringe, with clinical studies showing approximately 95 percent of at-home doses completed successfully.
Cardiovascular HealthJun 3, 2026
Icosapent ethyl (sold as Vascepa) is not your standard fish oil supplement. It's a prescription, purified form of EPA, one specific omega-3 fatty acid, and at 4 grams per day on top of statin therapy, it reduced major cardiovascular events by roughly 25% in high-risk patients. That's a striking number for a drug added to an already-optimized regimen. But the benefit comes with a trade-off that doesn't always make it into the headline: a measurable increase in atrial fibrillation risk.
The story of icosapent ethyl is really a story about residual risk, the cardiovascular danger that persists even after you've gotten your LDL cholesterol under control with a statin. For the right patient, this drug addresses that gap in a way few other add-on therapies have managed.
MedicationsJun 3, 2026
Rosuvastatin and atorvastatin are the two most prescribed high-intensity statins. Both lower LDL cholesterol and reduce cardiovascular risk, but they differ in potency, side effect profiles, and how individual patients respond. Here is what the research shows.
Cholesterol ManagementJun 3, 2026
In the largest trial of Repatha ever run, 27,564 patients took the drug for over two years, and the only side effect that happened more often than with placebo was a slightly sore injection site (2.1% vs 1.6%). That's it. Not muscle pain. Not memory problems. Not new diabetes. One mildly irritated patch of skin in roughly 1 in 50 people.
That mismatch between what worried patients searching online and what the data actually shows is the point of this article. Repatha (evolocumab) has now been studied across more than 60,000 patients in randomized trials and tracked in real-world registries on four continents. The picture is unusually consistent: most people tolerate it, a small minority quit because of it, and the scary stories floating around online aren't backed by the evidence.
Cardiovascular HealthJun 3, 2026
Your last cholesterol panel probably came back with a handful of familiar numbers: total cholesterol, LDL, HDL, triglycerides. If your LDL was under 100 mg/dL, your doctor may have said everything looks fine. But there's a growing body of evidence that one of the most important numbers for predicting heart disease isn't on the standard panel at all.
That number is apolipoprotein B, or {{apob:ApoB}}. It tells you something LDL cholesterol can't: exactly how many artery-damaging particles are floating through your bloodstream.
